Clinical Genomics receives CSIRO award for Entrepreneurship in Science
Thursday November 30, 2017 (Canberra, Australia)
Clinical Genomics was the proud recipient of the CEO Award for Entrepreneurship in Science at the 32nd Annual CSIRO Innovation Awards held in Canberra this week for developing a “liquid biopsy” blood test for colorectal cancer that is being used to identify early cancer relapse following colorectal cancer surgery. The Award was presented by CSIRO Chief Executive Dr Larry Marshall in recognition of the technology co-developed with CSIRO and Flinders Medical Centre as part of a decade-long partnership.
CSIRO acknowledged the distinguished partnership and combined research programs which has lead to the development of a blood based bowel cancer test and it’s subsequent commercialisation.
The technology, known as Colvera™, is a clinically validated blood test that sensitively and accurately detects tumour DNA. This presents a new opportunity for doctors to improve survival rates after surgery by detecting recurrence of the disease earlier and more accurately.
Chief Executive Officer Dr LaPointe said it was a great honour to be the recipient of this prestigious award but the overall goal was to continue to save lives.
About Clinical Genomics
Clinical Genomics is an international biotechnology company developing and marketing innovative products for colorectal cancer (CRC) diagnosis. With a broad intellectual property portfolio consisting of more than 95 patents, Clinical Genomics sells colorectal cancer screening and monitoring solutions. Clinical Genomics has offices and a CLIA-registered laboratory in Bridgewater NJ as well as FDA-registered and TGA-licensed IVD manufacturing in Edison, New Jersey and Sydney, Australia and a NATA-accredited laboratory in North Ryde, NSW Australia.For more information, please visit www.colveratest.com and www.clinicalgenomics.com.